zyrona 2 mg / 35 mikrog
orifarm generics (3) - cyproteronacetat / etinyløstradiol - tablett, drasjert - 2 mg / 35 mikrog
dienogest besins 2 mg
laboratoires besins international s.a.s. - dienogest - tablett - 2 mg
mulpleo (previously lusutrombopag shionogi)
shionogi b.v. - lusutrombopag - trombocytopeni - antihemoragika - mulpleo er angitt for behandling av alvorlig trombocytopeni hos voksne pasienter med kronisk leversykdom gjennomgår invasive prosedyrer.
marevan 2.5 mg
orifarm healthcare a/s - warfarinnatrium - tablett - 2.5 mg
erwinase 10000 e
porton biopharma limited - krisantaspase - pulver til injeksjons-/infusjonsvæske, oppløsning - 10000 e
rapilysin
actavis group ptc ehf - reteplase - hjerteinfarkt - antithrombotic agents - rapilysin is indicated for the thrombolytic treatment of suspected myocardial infarction with persistent st elevation or recent left bundle branch block within 12 hours after the onset of acute-myocardial-infarction (ami) symptoms.
cyklokapron 500 mg
viatris as - traneksamsyre - tablett, filmdrasjert - 500 mg
cyklokapron 500 mg
2care4 - traneksamsyre - tablett, filmdrasjert - 500 mg
osteopen vet 100 mg/ ml
chanelle pharmaceuticals manufacturing ltd - pentosanpolysulfatnatrium - injeksjonsvæske, oppløsning - 100 mg/ ml
duoplavin
sanofi winthrop industrie - clopidogrel, acetylsalicylic acid - acute coronary syndrome; myocardial infarction - antithrombotic agents - duoplavin er indisert for sekundær forebygging av atherotrombotiske hendelser hos voksne pasienter som allerede tar både klopidogrel og acetylsalisylsyre (asa). duoplavin is a fixed-dose combination medicinal product for continuation of therapy in:non st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary intervention (pci);st segment elevation acute myocardial infarction (stemi) in patients undergoing a stent placement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy. for ytterligere informasjon, vennligst referer til seksjon 5.